CDKL5 Gene Therapy

Proud to see Team CDKL5 Gene Therapy represented at the ASGCT Annual Meeting 2026 by Dr. Jacinthe Gingras, Paul Herzich, Dr. Lester Suarez, Dr. Pankaj Kumar, and Alvin Jogasuriya.

Attending one of the world’s most important meetings in gene and cell therapy created opportunities for new collaborations, meaningful scientific discussions, and shared momentum toward accelerating translational science for CDKL5. Every connection made brings us closer to better treatments and real hope for families affected by CDKL5. 

We’re honored to be invited by Lindonlight to share our journey in drug repurposing and advancing therapies for the rare disorder CDKL5 Deficiency Disorder.

Jainu Jogani will discuss how a parent-led mission evolved into a multi-modality therapeutic effort in translational science — spanning drug repurposing, gene therapy, and mRNA-based treatment approaches — including the identification of a promising repurposed drug candidate now approaching regulatory filing.

We’re looking forward to this opportunity to collaborate, share lessons learned, and continue accelerating treatments for rare diseases together.


We’re excited to be heading to in Boston!

Join Dr. Jacinthe Gingras and Dr. Pankaj Kumar as they share their work advancing gene therapy and CDKL5 mRNA approaches. From translational science to groundbreaking innovation, we’re looking forward to meaningful conversations and new collaborations.

If you’re attending, let’s connect!

📍 Boston, MA
📅 May 11–15, 2026

From research to real-world impact, our interns are part of something bigger—advancing hope for families.

Join our team as a:
✨ Marketing Intern
🔬 Research Intern

📩 Apply: [email protected]

We’re hiring a Marketing Intern this summer.

If you want hands-on experience and the chance to contribute to something that truly matters, this is your opportunity to support awareness and advocacy around CDKL5 gene therapy.

🧠 Real-world marketing experience�📣 Meaningful, mission-driven work�🌍 Fully virtual | 7 weeks

📅 Apply by May 15�📩 Send your CV to: [email protected]

If you or someone you know would be a great fit, please share. Please note, this will be an unpaid internship.

We are inviting motivated interns, age 14 and above, to join our 7-week virtual internship from June 1 to July 17 and contribute to meaningful CDKL5 projects across small molecule, gene therapy, and mRNA-based therapy.

This is a part-time, unpaid opportunity, but interns will receive full credit for their contributions, including recognition in publications where applicable. There is also a possibility of extension beyond the initial internship period.

This is a great opportunity to work alongside industry leaders, gain hands-on exposure to real-world biotech research, build a strong foundation in a cutting-edge field, and solve real world problems.

To apply, please email [email protected] with your resume and a brief note of interest. The interview process includes an initial screening, followed by two technical interviews. Apply by 8-May-2026.

Members of the CDKL5 Gene Therapy team will be at the upcoming workshop “Advancing Pediatric Cell and Gene Therapy Clinical Trials: Scientific, Ethical, Regulatory, and Practical Considerations” hosted by the FDA on April 9, 2026.

Dr. Jacinthe Gingras, PhD
Scientific Advisor,
Dr. Kruti Patel, PhD AAV Immunology Lead
Jainu Jogani, CDKL5 parent,
will be in attendance.